Etodolac Derivative eEF2K Inhibitor for Selective Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current small molecule kinase inhibitors are ineffective in inhibiting eukaryotic elongation factor 2 kinase (eEF2K), which is a critical driver in the progression of aggressive solid cancers, due to the lack of data on its 3D crystal structure and non-specificity of existing inhibitors.
Innovation Solution
Development of a novel etodolac derivative with a pyranoindole structure that acts as a specific eEF2K inhibitor, synthesized through amidation reactions and validated using computational modeling and molecular docking techniques.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional kinase inhibitors are used, then general kinase activity is inhibited, but eEF2K cannot be inhibited due to lack of specificity and structural data
Solution Approach 1:
The patent applies local quality by designing a inhibitor with specific structural features (pyrrolo[2,3-b]pyridine core with particular substituent patterns) that target the unique structural characteristics of eEF2K's ATP binding site, rather than using general kinase inhibitor structures. This localized structural optimization enables selective inhibition of eEF2K while sparing other kinases.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituent types, positions, and configurations on the pyrrolo[2,3-b]pyridine core) to optimize both binding affinity to eEF2K and selectivity against other kinases. This iterative parameter optimization allows the inhibitor to achieve high specificity for eEF2K.
2Manufacturing precision
If small molecule inhibitors are developed without 3D crystal structure data, then drug discovery is hampered, but homology modeling can be used as an alternative
Solution Approach 1:
The patent applies copying by creating a homology model of eEF2K's 3D structure based on the known crystal structures of related kinases (ATM, ATR, DNA-PKcs). This computational copy of the structure provides sufficient accuracy for rational drug design and molecular docking studies, enabling inhibitor development without requiring the actual eEF2K crystal structure.
Solution Approach 2:
The patent uses homology modeling as an intermediary approach, where the known structures of evolutionarily related kinases serve as mediators to infer the 3D structure of eEF2K. This intermediary modeling approach bridges the gap between available structural data and the needed eEF2K structure for inhibitor design.
3Reliability
If existing eEF2K inhibitors are used, then some inhibition is achieved, but they lack specificity and require high concentrations
Solution Approach 1:
The patent applies local quality by incorporating specific functional groups (such as fluorine atoms at particular positions, specific hydroxyl group configurations, and defined substituent patterns) on the pyrrolo[2,3-b]pyridine core that interact with unique residues in eEF2K's binding site. These localized structural features provide both high potency and selectivity for eEF2K inhibition.
Data Source
AI summary
A compound derivative is provided, where R in the compound of formula A is 4-methylpiperazine, and the compound derivative can be used in the treatment of cancer and other diseases through the development of small molecules as eukaryotic elongation factor 2 kinase (eEF2K) enzyme inhibitors that are active in breast, pancreatic, brain, ovarian, lung, skin and blood cancers.